Welcome to the Session of

Unipril (Ramipril BP 2.5 & 5)

Presented by

Mohammed Moshiur Rahaman

Brand Executive

Brand Management Department

The ACME Laboratories Ltd.

Product Information

Brand Name : Unipril 2.5 & 5 Composition : Ramipril BP 2.5 & 5 Therapeutic group : Antihypertensive (ACE inhibitor) Product group : Pack Size : 3 X10’s Unit Price : 5.01 tk/unit (2.5 mg) tablet

8.04 tk/unit (5 mg) tablet

Mechanism of Action

Unipril inhibits conversion of Angiotensin I to Angiotensin II by inhibiting Angiotensin converting

Enzyme (ACE).

Angiotensinogen (from the liver)

Renin from Kidney

Angiotensin I

ACE enzyme

No production of Angiotensin II

Blood pressure decreases

Unipril inhibits ACE enzyme

Market Information:

The market size of Ramipril is 22 crore (appr.) with Growth 15.9%.

Brand Company Sales value(crore) yearly

Ramoril Incepta 7.92

Ramace Opsonin 3.32

Tritace Sanofi Aventis 2.91

Ripril Square 1.50

Piramil Sandoz 1.41

Indications

Mild to severe hypertension, where it may be used alone or in combination with thiazide diuretics.

Congestive heart failure To reduce the risk of stroke, myocardial infarction and

death from cardiovascular events in patients with a history of cardiovascular diseases

Proteinuric non-diabetic nephropathy

Unipril reduces CV events in high risk patientsAccording to HOPE study, Ramipril significantly reduces the rate of death, myocardialinfarction and stroke in a broad range of high risk patients who are not known to have alow ejection fraction or heart failure.

…..An appropriate choice for CV patients

Unipril shows the highest survival rate among all ACEinhibitorsAfter the incidence of acute MI, patients were treated with different ACEinhibitors. Ramipril shows significant lower mortality than other ACEinhibitors.

……Better for MI patients

Unipril offers beneficial effects in people with diabeticpatients According to MICRO-HOPE study, Ramipril significantly reduces thecardiovascular death, stroke and heart attack in patients with diabetes.

……A perfect choice for diabetic

patients

Unipril provides effective improvement of all

parameters in Chronic Nephropathy

 According to REIN study, in patient with chronic nephropathy & high risk of

rapid progression of ESRD, Ramipril reversed the tendency of GFR to decline

with time. Moreover, a treatment period of sufficient duration (36 months )

eliminated the need for dialysis.

……shows effective and consistent renoprotective effect

Use In Pregnancy And Lactation

PregnancyPregnancy should be excluded before start of treatment withRamipril and avoided during treatment. However, ifpregnancy is detected, Unipril (Ramipril) should bediscontinued as early as possible unless continued use isconsidered life saving.

LactationRamipril should not be used during lactation.

Target Doctors

Cardiologist Neurologist Medicine specialist General practitioners Hospital practitioners

Highlighting Points

Unipril… is an appropriate choice for CV patients prevents premature death in acute MI reduces the atherosclerosis progression offers beneficial effects in diabetic patients ensures effective renal protection shows better tolerability

Thank you all